Get the Stockscreener App
2.60
4.00%
0.10
Bionexus Gene Lab Corp stock is traded at $2.60, with a volume of 16,130.
It is up +4.00% in the last 24 hours and up +28.77% over the past month.
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.
See More
Previous Close:
$2.50
Open:
$2.43
24h Volume:
16,130
Relative Volume:
0.18
Market Cap:
$6.29M
Revenue:
$5.31M
Net Income/Loss:
$-2.90M
P/E Ratio:
-1.7503
EPS:
-1.4855
Net Cash Flow:
$-1.18M
1W Performance:
+19.54%
1M Performance:
+28.77%
6M Performance:
-36.89%
1Y Performance:
-12.31%
1-Day Range:
$2.43
$2.60
1-Week Range:
$1.07
$2.70
52-Week Range:
$1.07
$15.60
Bionexus Gene Lab Corp Stock (BGLC) Company Profile
Name
Bionexus Gene Lab Corp
Sector
Industry
Phone
1-307-241-6898
Address
10-2 TOWER B, VERTICAL BUSINESS SUITE,, KUALA LUMPUR
Compare BGLC vs MOBBW, SHMD, GOODO, PSNYW, DWLD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BGLC
BioNexus Gene Lab Corp Common stock
|
0.343 | 201.51M | 0 | 0 | 0 | 0.00 |
MOBBW
Mobilicom Limited Warrants
|
2.45 | 3.33B | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
6.19 | 397.06M | 52.15M | -21.46M | 0 | -0.4675 |
GOODO
Gladstone Commercial Corporation
|
20.19 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
2.83 | 254.39M | 2.07B | -1.42B | -1.37B | -0.6765 |
DWLD
Davis Select Worldwide ETF
|
47.19 | 0 | 0 | 0 | 0 | 0.00 |
Bionexus Gene Lab Corp Stock (BGLC) Latest News
12 Industrials Stocks Moving In Thursday's Pre-Market Session - Benzinga
BioNexus Gene Lab Corp (BGLC) Slips 4.1%: Testing Key Support at $2.09Elliott Wave Entry - newsline.com
BioNexus Gene Lab Calls for Malaysia–China Biotech Co-Development and Precision Healthcare Collaboration 1 - Minichart
BioNexus Gene Lab Urges Malaysia–China Co-Development of Biotech Platforms After Kuala Lumpur Forum - TradingView
BioNexus Gene Lab (Nasdaq: BGLC) pushes Malaysia–China biotech co-development model - Stock Titan
BioNexus Gene Lab Corp (BGLC) Declines 8.33% as Stock Approaches Key SupportHigh Beta Stocks - The Legal Advocate
BioNexus Gene Lab Corp (BGLC) Slides 4.17% as Support Level Nears – Key Levels to WatchRating Change - newsline.com
BioNexus Gene Lab Corp (BGLC) Slides 6.25%: Key Support Zone Under ScrutinyCash Flow Strong Stocks - The Legal Advocate
BioNexus Gene Lab Corp. Calls for Malaysia-China Biotechnology Collaboration Focused on Joint Development - geneonline.com
BioNexus Gene Lab Corp. Calls for Malaysia–China - GlobeNewswire
Turning Malaysia into a bridge for China’s biotech ambitions - Stock Titan
BioNexus Gene Lab Stock Edges Up While Nasdaq Microcap Faces Chemrex Cash Battle - Bez Kabli
12 Industrials Stocks Moving In Wednesday's After-Market Session - Sahm
BioNexus Gene Lab Corp (BGLC) Surges 8.44%: Testing Key Resistance at $2.30Channel Breakout - The Legal Advocate
BioNexus Gene Lab (BGLC) Extends Decline, Tests Key Support at $1.92Crowd Entry Signals - Newser
BioNexus Gene Lab Corp 1Q 2026: Revenue $22.84K, EPS ($0.23) — 10-Q Summary - TradingView
BioNexus Gene Lab Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[10-Q] BioNexus Gene Lab Corp Quarterly Earnings Report - Stock Titan
BGLC | BioNexus Gene Lab Corp Insider Trading - Quiver Quantitative
TradingKey - TradingKey
Is BioNexus Lab (BGLC) stock fading in strength |Community Buy Alerts - newser.com
BioNexus Lab (BGLC) Risk Reward Ratio | BioNexus Gene Lab posts strong revenue, net lossCertified Trade Ideas - Xã Vĩnh Công
BioNexus Gene Lab: Chemical Raw Materials & Genomic Screening Business Overview, Growth Strategies, and Market Insights 19233034 - Minichart
BioNexus Gene Lab 10-K: Revenue $7.42M, EPS $(1.61) - TradingView
[10-K] BioNexus Gene Lab Corp Files Annual Report - Stock Titan
BioNexus Gene Lab Corp. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Analyst Upgrade: Will BioNexus Gene Lab Corp stock recover after earningsPortfolio Profit Report & Precise Entry and Exit Recommendations - baoquankhu1.vn
BioNexus Gene Lab Corp. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Will BioNexus Lab (BGLC) Stock Grow in 2026 | Price at $2.15, Down 4.41%Put Support - newsline.com
Ideas Watch: Does BioNexus Gene Lab Corp stock reflect fundamentalsShare Buyback & Entry Point Strategy Guides - baoquankhu1.vn
BGLC Stock Price, Quote & Chart | BIONEXUS GENE LAB CORP (NASDAQ:BGLC) - ChartMill
How is BioNexus Lab (BGLC) Stock performing in 2026 | Price at $2.30, Up 1.71%Weak Sell Signals - The Legal Advocate
Can BioNexus Lab (BGLC) Stock Go Higher | Price at $2.23, Up 0.98%Bollinger Expansion - newsline.com
BGLC SEC FilingsBionexus Gene La 10-K, 10-Q, 8-K Forms - Stock Titan
[NT 10-K] BioNexus Gene Lab Corp SEC Filing - Stock Titan
12 Industrials Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Volume Recap: Can BioNexus Gene Lab Corp be the next market leader2026 Pullback Review & Stock Portfolio Risk Control - baoquankhu1.vn
Portfolio Update: Is BioNexus Gene Lab Corp in a consolidation phase2026 Sector Review & Daily Growth Stock Tips - baoquankhu1.vn
Will BioNexus Gene Lab Corp stock recover after earningsMarket Activity Recap & Safe Entry Trade Signal Reports - baoquankhu1.vn
Aug Highlights: Does LTRY have declining or rising EPS2026 Intraday Action & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Tech Rally: Will BioNexus Gene Lab Corp outperform its industry peersPortfolio Profit Report & Free Reliable Trade Execution Plans - baoquankhu1.vn
12 Industrials Stocks Moving In Wednesday's Pre-Market Session - Benzinga
BioNexus Gene Lab (NASDAQ: BGLC) taps new CCO to drive Fidelion VitaGuard MRD commercialization - Stock Titan
BioNexus Gene Lab appoints commercial officer at Fidelion By Investing.com - Investing.com Nigeria
BioNexus Gene Lab appoints commercial officer at Fidelion - Investing.com India
BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard MRD Platform - Bitget
BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform - The Manila Times
BioNexus Gene Lab Corp. Appoints Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics - Quiver Quantitative
Cancer relapse blood tests: Fidelion hires 15-year oncology diagnostics veteran - Stock Titan
12 Industrials Stocks Moving In Monday's Intraday Session - Sahm
Bionexus Gene Lab Corp Stock (BGLC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):